An update on serum amyloid A–LDL and its potential use for dyslipidemic patients receiving lipid-modulating treatment

Abstract

LDL is modified under pathological conditions associated with inflammation and oxidative stress. Serum amyloid A–LDL (SAA–LDL) is considered a possible marker of atherosclerotic diseases. The present article reviews the clinical studies of SAA–LDL in dyslipidemic patients being treated with lipid-modulating drugs. Although limited studies are currently available, a therapeutic reduction of SAA–LDL levels could be seen following treatment of dyslipidemic patients with eicosapentaenoic acid, fibrates and statins. The SAA–LDL level may potentially be used to monitor the effectiveness of treatment in these patients, while the clinical utility of measuring the SAA–LDL level has yet to be established in large prospective clinical trials. Future studies are warranted to confirm the clinical relevance of SAA–LDL.

Keywords::

• atherosclerosis
• eicosapentaenoic acid
• fibrate
• lipid disorder
• statin